2-Aminopyrazolo[1,5-a]pyrimidines as potent and selective inhibitors of JAK2

Bioorganic and Medicinal Chemistry Letters

Volumn 19, Issue 23, 2009, Pages 6529-6533

  Ledeboer, Mark W ^a   Pierce, Albert C ^a   Duffy, John P ^a   Gao, Huai ^a   Messersmith, David ^a   Salituro, Francesco G ^a   Nanthakumar, Suganthini ^a   Come, Jon ^a   Zuccola, Harmon J ^a   Swenson, Lora ^a   Shlyakter, Dina ^a   Mahajan, Sudipta ^a   Hoock, Thomas ^a   Fan, Bin ^a   Tsai, Wan Jung ^a   Kolaczkowski, Elaine ^a   Carrier, Scott ^a   Hogan, James K ^a   Zessis, Richard ^a   Pazhanisamy, S ^a   Bennani, Youssef L ^a   more..

^a VERTEX PHARMACEUTICALS   (United States)

Author keywords

2 Amino pyrazolo 1,5 a pyrimidines; JAK2; Janus kinase 2; Kinase inhibitor; Polycythemia vera; Structure based design

Indexed keywords

2 AMINOPYRAZOLO[1,5 A]PYRIMIDINE; 4 AMINOPYRAZOLO[3,4 D]PYRIMIDINE; JANUS KINASE 2 INHIBITOR; JANUS KINASE INHIBITOR; PYRIMIDINE DERIVATIVE; UNCLASSIFIED DRUG;

ARTICLE; CHEMICAL STRUCTURE; CRYSTAL STRUCTURE; ENANTIOSELECTIVITY; ENZYME ACTIVITY; ENZYME INHIBITION; HYDROGEN BOND; MICROWAVE IRRADIATION; SIGNAL TRANSDUCTION; STRUCTURE ACTIVITY RELATION; X RAY CRYSTALLOGRAPHY;

CRYSTALLOGRAPHY, X-RAY; DRUG DISCOVERY; JANUS KINASE 2; MODELS, MOLECULAR; MOLECULAR STRUCTURE; PROTEIN KINASE INHIBITORS; PYRAZOLES; PYRIMIDINES; SIGNAL TRANSDUCTION; STEREOISOMERISM; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 71749093137     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2009.10.053     Document Type: Article

References (31)

1. Vardiman J.W., Harris N.L., and Brunning R.D. Blood 100 (2002) 2292
2. Leonard W.J., and O'Shea J.J. Annu. Rev. Immunol. 16 (1998) 293
3. Wilks A.F. Semin. Cell Dev. Biol. 19 (2008) 319
4. James C., Ugo V., Le Couédic J.P., Staerk J., Delhommeau F., Lacout C., Garçon L., Raslova H., Berger R., Bennaceur-Griscelli A., Villeval J.L., Constantinescu S.N., Casadevall N., and Vainchenker W. Nature 434 (2005) 1144
5. Levine R.L., Wadleigh M., Cools J., Ebert B.L., Wernig G., Huntly B.J.P., Boggon T.J., Wlodarska I., Clark J.J., Moore S., Adelsperger J., Koo S., Lee J.C., Gabriel S., Mercher T., D'Andrea A., Froehling S., Doehner K., Marynen P., Vandenberghe P., Mesa R.A., Tefferi A., Griffin J.D., Eck M.J., Sellers W.R., Meyerson M., Golub T.R., Lee S.J., and Gilliland D.G. Cancer Cell 7 (2005) 387
6. Baxter E.J., Scott L.M., Campbell P.J., East C., Fourouclas N., Swanton S., Vassiliou G.S., Bench A.J., Boyd E.M., Curtin N., Scott M.A., Erber W.N., and Green A.R. Lancet 365 (2005) 1054
7. Kralovics R., Passamonti F., Buser A.S., Teo S.-S., Tiedt R., Passweg J.R., Tichelli A., Cazzola M., and Skoda R.C. N. Eng. J. Med. 352 (2005) 1779
8. For a recent review on the role of JAK2 mutations in myleoproliferative disorders see:. Morgan K.J., and Gilliland D.G. Annu. Rev. Med. 59 (2008) 213
9. Lucet I.S., Fantino E., Styles M., Bamert R., Patel O., Broughton S.E., Walter M., Burns C.J., Treutlein H., Wilks A.F., and Rossjohn J. Blood 107 (2006) 176
10. Antonysamy S., Hirst G., Park F., Sprengeler P., Stappenbeck F., Steensma R., Wilson M., and Wong M. Bioorg. Med. Chem. Lett. 19 (2009) 279
11. Williams N.K., Bamert R.S., Patel O., Wang C., Walden P.M., Wilks A.F., Fantino E., Rossjohn J., and Lucet I.S. J. Mol. Biol. 387 (2009) 219
12. Manshouri T., Quintás-Cardama A., Nussenzveig R.H., Gaikwad A., Estrov Z., Prchal J., Cortes J.E., Kantarjian H.M., and Verstovsek S. Cancer Sci. 99 (2008) 1265
13. Crystallographic data for the structures in this paper have been deposited with the RCSB Protein Data Bank. Compound 12, PDB accession code: 3IO7; compound 42, PDB accession code: 3IOK.
14. Boggon T.J., Li Y., Manley P.W., and Eck M.J. Blood 106 (2005) 996
15. Nyberg W.H., and Cheng C.C. J. Heterocycl. Chem. 1 (1964) 1
16. Marchal L., Promel R., Martin R.H., and Cardon A. Bull. Soc. Chim. Belg. 69 (1960) 177
17. Schnyder A., Indolese A.F., Maetzke T., Wenger J., and Blaser H.-U. Synlett (2006) 3167
18. Indolese A.F., Schynder A., Aemmer T., Nsenda T., and Portmann R.M. In: Hermann W.A. (Ed). Synthetic Methods in Organometallic and Inorganic Chemistry Vol. 10 (2002), Thieme, New York 105
19. Elnagdi M.H., Sallam M.M.M., and Ilias M.A.M. Helv. Chim. Acta 58 (1975) 1944
20. Shaaban M.R., Saleh T.S., and Farag A.M. Heterocycles 71 (2007) 1765
21. Sawayama T., Yamamoto R., Kinugasa H., and Nishimura H. Heterocycles 8 (1977) 299
22. Nagashima S., Yokota M., Nakai E.-I., Kuromitsu S., Ohga K., Takeuchi M., Tsukamoto S.-I., and Ohta M. Bioorg. Med. Chem. 15 (2007) 1044
23. Chiral benzyl amines were prepared following the methods described in:. Liu G., Cogan D.A., and Ellman J.A. J. Am. Chem. Soc. 119 (1997) 9913
24. For the convenient preparation of small secondary amines see:. Dubowchik G.M., Michne J.A., and Zuev D. Bioorg. Med. Chem. Lett. 14 (2004) 3147
25. Coste J., Le-Nguyen D., and Castro B. Tetrahedron Lett. 31 (1990) 205
26. Frerot E., Coste J., Pantaloni A., Dufour M.N., and Jouin P. Tetrahedron 47 (1991) 259
27. i determinations refer to Supplementary data and the following references:. Fox T., Coll J.T., Ford P.J., Germann U.A., Porter M.D., Pazhanisamy S., Fleming M.A., Galullo V., Su M.-S., and Wilson K.P. Protein Sci. 7 (1998) 2249
28. Morrison J.F., and Stone S.R. Comments Mol. Cell. Biophys. 2 (1985) 347
29. 50 determinations using TF-1 and HT-2 cells refer to Supplementary data.
30. Taylor R., and Kennard O. J. Am. Chem. Soc. 104 (1982) 5063
31. Pierce A.C., Sandretto K.L., and Bemis G.W. Proteins 49 (2002) 567